SUGAR-seq, a single-cell method developed by researchers in Australia, is a first step towards analyzing differences in glycosylation in various cell types.
Using technology rooted in pharmacogenomics testing for medical cannabis, the firm claims it can predict immune response to SARS-CoV-2 and test biomarkers for pharma.
In Nature this week: genetic and proteomic data gives Alzheimer's disease development insights, whole-genome doubling could be targeted in cancer, and more.
